Trial Profile
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin; Paclitaxel
- Indications Adenosquamous carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 05 Dec 2022 Status changed from active, no longer recruiting to completed.
- 14 Sep 2021 Results published in the JAMA: the Journal of the American Medical Association
- 08 Jun 2021 Primary endpoint (OS) has been met as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology